TRS005

Phase 2Small molecule

ZZhejiang Teruisi Pharmaceutical Inc.

TRS005 is one of 11 small molecule programs targeting Doxorubicin. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DoxorubicinNot yet recruiting

Phase 2Not yet recruiting

DoxorubicinPhase 2

Not yet recruiting

Phase 2Phase 2

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Phase 2

#DrugCompanyPhaseTrials

Vizimpro

Pfizer

Phase 2

1 2

P1101

PPharmaEssentia Japan K.K.

Phase 3

1 3

ABSK-011

AAbbisko Therapeutics Co, Ltd

Phase 2

1 4

ABSK061

AAbbisko Therapeutics Co, Ltd

Phase 2

1 5

TRS005

ZZhejiang Teruisi Pharmaceutical Inc.

Phase 2

1 6

Taletrectinib

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 7

SB17170

SSPARK Biopharma

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Phase 2

NCT06886139

Q3 2028

Phase 1/2Not yet recruiting

Doxorubicin

NCT07035379

Clinical

Trials by Indication[1]

Phase 21 trial

A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

Not yet recruiting·ZZhejiang Teruisi Pharmaceutical Inc.·Phase 2·NCT06886139·139 enrolled

Doxorubicin1 trial

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Not yet recruiting·ZZhejiang Teruisi Pharmaceutical Inc.·Phase 1/2·NCT07035379·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TRS005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRS005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRS005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Teruisi Pharmaceutical Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: ZZhejiang Teruisi Pharmaceutical Inc.

TRS005

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Phase 21 trial

Doxorubicin1 trial

References

Drug Info

Quick Facts

Related News